A Comprehensive Review of Managing In-Stent Restenosis

Prashar A, Jerzyna L and Roy J

Published on: 2022-01-16

Abstract

Although the widespread adoption of drug eluting stents (DES) has seen a dramatic reduction in rates of in-stent restenosis (ISR), it remains a significant barrier in the long-term management of coronary artery disease.

ISR is defined angiographically as a greater than 50% stenosis at the site of previous drug eluting (DES) or bare metal stent (BMS) placement [1]. Clinical restenosis is the presence of an angiographic restenosis with symptoms of coronary ischaemic or a positive functional ischaemia study. Angiographic stenoses above 70% are also typically classified as clinically significant even in the absence of ischaemic symptoms